Viewing Study NCT00004494



Ignite Creation Date: 2024-05-05 @ 11:19 AM
Last Modification Date: 2024-10-26 @ 9:04 AM
Study NCT ID: NCT00004494
Status: COMPLETED
Last Update Posted: 2022-05-04
First Post: 1999-10-18

Brief Title: Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis
Sponsor: Stony Brook University
Organization: Stony Brook University

Study Overview

Official Title: None
Status: COMPLETED
Status Verified Date: 2022-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: OBJECTIVES

I Determine the maximum tolerated dose of vasoactive intestinal peptide in patients with acute respiratory distress syndrome

II Evaluate the safety and pharmacodynamic activity of this peptide in these patients
Detailed Description: PROTOCOL OUTLINE

This is a dose escalation study

Patients receive vasoactive intestinal peptide VIP IV over either 6 or 12 hours

Cohorts of 3 patients each receive escalating doses of VIP over either 6 or 12 hours until the maximum tolerated dose is determined

Patients are followed for 30 days

Study Oversight

Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
Secondary ID Type Domain Link
FD-R-0001488 OTHER_GRANT FDA Orphan Drug Products None
SUNY-SB-FDR001488 None None None
SUNY-SB-96-077 None None None
SUNY-SB-98-2606 None None None